Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Prof Enriqueta Felip (Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain), Dr Antonio Passaro (European Institute of Oncology, Milan, Italy), Dr Alex Spira (Virginia Cancer Specialists Research Institute, Fairfax, USA) and Prof Ignacio Gil-Bazo (Hospital Vithas Vitoria, Vitoria, Spain) discuss the latest in EGFR positive NSCLC data from the 2025 World Conference on Lung Cancer.
They discuss combination therapies and clinical trial results from the PALOMA-2, COCOON, COMPEL, FLAURA2 and HARMONi studies.
The panel highlights the development of subcutaneous amivantamab and further discuss antibody-drug conjugates which are expected to enhance treatment protocols.
| First-line osimertinib + chemotherapy versus osimertinib monotherapy in EGFRm advanced NSCLC: FLAURA2 final overall survival | |
| Ivonescimab vs placebo plus chemo, phase 3 in patients with EGFR+ NSCLC progressed with 3rd gen EGFR-TKI treatment: HARMONi | |
| COMPEL: Osimertinib + platinum-based chemotherapy in patients with EGFRm advanced NSCLC and progression on first-line osimertinib | |
| First-line subcutaneous amivantamab plus chemotherapy in EGFR exon 20 insertion-mutated advanced NSCLC: Results from PALOMA-2 | |
| Subcutaneous amivantamab administered every 4 weeks plus lazertinib in first-line EGFR-mutated advanced NSCLC (PALOMA-2) | |
| Enhanced vs standard dermatologic management with amivantamab-lazertinib in EGFRm advanced NSCLC: The COCOON global RCT | |
| What's next for EGFR mutant NSCLC? |
